Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy", in the European Journal of Clinical Investigation. Metabolon's non-targeted biochemical profiling (metabolomics) platform was used to identify biochemical biomarkers of primary dilated cardiomyopathy (DCM) and potential therapeutic targets for DCM. The study was carried out by Metabolon scientists in collaboration with A. J. Marin and colleagues from The University of Texas Health Science Center and Texas Heart Institute at Houston.

“Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy”

The advent of ACE inhibitors and β-blockers has provided significant advances in the treatment of systolic heart failure. Yet, the mortality and morbidity of heart failure patients remains high and the incidence of the disease continues to increase. In this report the authors showed the utility of Metabolon's biochemical profiling technology to provide insight into cardiac metabolism in patients with primary DCM. Changes in several bioactive plasma metabolites related to oxidative stress such as indole-3-propionate (IPA) and stachydrine were measured in DCM patients. In addition, results from Metabolon's global, non-targeted analysis suggest a role of the gastrointestinal tract and gut microflora in heart failure.

Source: Metabolon